K
Kurome Therapeutics
Kurome therapeutics is developing therapies to target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive…
About Kurome Therapeutics
Kurome Therapeutics is a preclinical-stage biopharmaceutical company focused on developing a new class of kinase inhibitors to treat hematological cancers. The company was established in 2019 and launched in 2020, built upon the foundational research of Dr. Daniel Starczynowski at Cincinnati Children's Hospital Medical Center, in collaboration with the National Center for Advancing Translational Sciences (NCATS) at the NIH. Dr. Starczynowski, a leading expert in IRAK 1/4 signaling pathways in cancer, has dedicated his research to understanding the molecular basis of hematologic malignancies, particularly Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). His lab's work, which began around 2013, identified a novel therapeutic target, and this scientific basis was licensed by Kurome to be developed into commercial products.
The company's primary focus is on developing therapies that target cancer cells that have co-opted the body's immune signaling pathways to survive and resist treatment. Kurome's core technology is a series of small-molecule inhibitors that dually target IRAK1/4 (interleukin-1 receptor-associated kinase 1 and 4) and pan-FLT3. This dual-action approach is designed to overcome the adaptive resistance mechanisms that often lead to relapses in cancer patients undergoing traditional chemotherapy or other targeted treatments. The company's business model centers on the research and development of these proprietary compounds, with the ultimate goal of bringing them through clinical trials and to market. Revenue generation will be contingent upon successful drug development, potential licensing agreements with larger pharmaceutical partners, and eventual sales of approved therapies.
Kurome's initial therapeutic candidates are being developed for patients with poor-prognosis Acute Myeloid Leukemia (AML) and pre-leukemic conditions like Myelodysplastic Syndromes (MDS). The lead compound, KME-0584, emerged after synthesizing and testing over 1,600 derivative compounds to optimize its properties. Preclinical studies have shown that these inhibitors have a broad range of efficacy in patient-derived cell lines and can work synergistically with existing treatments like Venclexta®. A significant milestone was achieved when the FDA approved the Investigational New Drug (IND) application for KME-0584, allowing clinical trials to begin. The company has secured significant funding to advance its research, including a $4 million seed round in February 2020 and a $15 million Series A financing in June 2021, co-led by Medicxi and Affinity Asset Advisors, with participation from founding investor CincyTech.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2021 | $15M | $60M | CincyTech · Medicxi · Affinity Asset Advisors | — |
| SEED✓Equity / VC | Apr 2020 | — | — | CincyTech | — |
Growth signals
Latest recorded traffic for Kurome Therapeutics is 1.8K monthly website visits, up 50% over the last three months. Kurome Therapeutics's team declined 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Kurome Therapeutics in the Cincinnati ecosystem
The Kurome Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
CincyTech
Series A2 investors entered at this stage
Affinity Asset Advisors
Medicxi
Other known investors2 additional known investors
Cincinnati Children’s Hospital Medical Center
National Institutes of Health
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kurome Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kurome Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









